Are there specific liver function tests to monitor with tigecycline?

Yes. Tigecycline can cause liver enzyme elevations and, less commonly, more serious hepatic injury, so it’s reasonable to monitor liver function tests (LFTs) during therapy.

Commonly monitored LFTs:

• ALT (alanine aminotransferase)
• AST (aspartate aminotransferase)
• Alkaline phosphatase (ALP)
• Total bilirubin (and sometimes direct bilirubin)
• Albumin (optional, more reflective of longer-term function)
• Prothrombin time/INR (optional, more concerning for impaired hepatic synthetic function)

Practical approach (typical in many clinical settings):

• Check baseline LFTs (ALT/AST, bilirubin ± ALP).
• Recheck periodically during treatment—often at least weekly, and sooner/more frequently if:
  • baseline abnormalities exist,
  • treatment is prolonged,
  • the patient has other liver risk factors (e.g., hepatitis, cirrhosis),
  • there are symptoms suggesting hepatic issues (jaundice, dark urine, RUQ pain, pruritus, unexplained nausea).

Escalation / action:

• If there are rising transaminases or bilirubin, clinicians typically reassess for other causes (drug interactions, sepsis-related cholestasis, viral hepatitis, etc.) and consider holding or stopping tigecycline depending on the degree and pattern of injury.

If you tell me the patient’s situation (baseline LFT values, duration of therapy, and any symptoms/other meds), I can suggest a more tailored monitoring frequency and what patterns are most concerning.